<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mucocutaneous type of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> (MCBD) is a multisystemic <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> with oral and <z:hpo ids='HP_0003249'>genital ulcers</z:hpo> with or without <z:mp ids='MP_0001212'>skin lesions</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A solid phase, two-site sequential chemiluminescent immunometric assay was used to measure serum levels of interleukin (IL)-6, IL-8 and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-alpha in 54 <z:mpath ids='MPATH_458'>normal</z:mpath> control subjects and in 64 MCBD patients before and after treatment with levamisole plus <z:chebi fb="0" ids="23359">colchicine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: We found that 67%, 83% or 67% of MCBD patients had a serum IL-6, IL-8 or TNF-alpha level greater than the upper <z:mpath ids='MPATH_458'>normal</z:mpath> limit of 4.7, 8.7 or 7.4 pg/ml, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>The mean serum level of IL-6 (9.9 +/- 2.4 pg/ml, P &lt; 0.005), IL-8 (107.5 +/- 21.4 pg/ml, P &lt; 0.001) or TNF-alpha (22.5 +/- 4.1 pg/ml, P &lt; 0.001) in 64 MCBD patients was significantly higher than that (2.1 +/- 0.2, 5.7 +/- 0.2 or 3.8 +/- 0.2 pg/ml for IL-6, IL-8 or TNF-alpha level, respectively) in <z:mpath ids='MPATH_458'>normal</z:mpath> control subjects </plain></SENT>
<SENT sid="4" pm="."><plain>In 43 MCBD patients with <z:hpo ids='HP_0000001'>all</z:hpo> the serum IL-6, IL-8 and TNF-alpha levels higher than their upper <z:mpath ids='MPATH_458'>normal</z:mpath> limits, treatment with levamisole plus <z:chebi fb="0" ids="23359">colchicine</z:chebi> for a period of 0.5-11.5 (mean, 3.2 +/- 2.4) months could significantly reduce the mean serum IL-6, IL-8 and TNF-alpha levels from 9.0 +/- 1.7 to 1.6 +/- 0.2 pg/ml (P &lt; 0.001), 134.6 +/-28.2-6.0 +/- 0.4 pg/ml (P &lt; 0.001) and 25.7 +/- 5.6-3.5 +/- 0.4 pg/ml (P &lt; 0.001), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Treatment with levamisole and <z:chebi fb="0" ids="23359">colchicine</z:chebi> can result in a significant reduction of serum IL-6, IL-8 or TNF-alpha level in MCBD patients </plain></SENT>
</text></document>